A pharmaceutical company has expanded its recall of the anti-anxiety drug clonazepam due to a potential mislabeling issue. The manufacturer Endo Inc. stated that the drug was being recalled because of a potential life-threatening mislabeling about the product's strength on its carton. The drug is Clonazepam Orally Disintegrating Tablets, USP, and was packaged by Par Pharmaceutical before being acquired by Endo. The recall was initiated due to an error by a third-party packager that resulted in incorrect strength and National Drug Code on some cartons. Consuming a higher dose of clonazepam can lead to adverse effects such as sedation, confusion, and respiratory depression, especially for certain patient populations. The recalled lots contain 60 tablets packed into blister strips, and the company has not received any adverse reaction reports so far. The drug is commonly used to treat anxiety and other disorders and is sold under various brand names. Clonazepam is ranked as the 57th most prescribed medication in the U. S. The FDA has listed the recalled products and their NDC numbers on its website. Symptoms of a clonazepam overdose include changes in consciousness, speech patterns, coordination, hallucinations, and muscle weakness. Wholesalers and pharmacies have been advised to stop distributing the product, and consumers are urged to discontinue use and consult a physician if they suspect incorrect dosing.
Subscribe to:
Post Comments (Atom)
$750k grant secured for WNC river cleanup
Asheville nonprofit MountainTrue has landed a $750,000 grant to expand its river cleanup program after Hurricane Helene. The group h...
No comments:
Post a Comment